Home
Our ServicesConnect Education Workshops
HomeOur ServicesConnect Education Workshops
Connect Education Workshops About Treatment
You can also browse all resources about treatment»
Upcoming Workshops
For Breast Cancer
For Leukemia
For Lung Cancer
For Mantle Cell Lymphoma
For Ovarian Cancer
For Prostate Cancer
For Thyroid Cancer
For Uterine Cancer
Past workshops
For All Cancers
- Diverse Populations Participating in Decisions About Your Care With Your Health Care TeamPart II of How Health Care Disparities May Influence Your Cancer Treatment and Care
- Understanding Diagnostic Technologies and Biomarkers
- Clinical Trials: How They Transform the Treatment of Cancer
- Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care: With Tips and Strategies to Find the Best Cancer Treatment and Health Care Team for YouPart I of How Health Care Disparities May Influence Your Cancer Treatment and Care
- Understanding Diagnostic Technologies and Biomarkers
- Chemotherapy Treatment Side Effects: Prevention & Management
- Diverse Populations Participating in Decisions about Your Care with Your Health Care TeamPart II of How Health Care Disparities May Influence Your Cancer Treatment and Care
- Clinical Trials: How They Transform the Treatment of Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care: With Tips & Strategies to Find the Best Cancer Treatment & Health Care Team for YouPart I of How Health Care Disparities May Influence Your Cancer Treatment and Care
- CAR T-Cell Therapy: What's New
- Preventing, Managing & Treating Infection in Adults Living with Cancer
- What’s New in Precision Medicine
- How Health Care Disparities May Influence Your Cancer Treatment & Care
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Taking Your Pills on Schedule: Why It Is So Important in Managing Cancer
- Emerging Importance of Telemedicine/Telehealth Appointments in Communicating with Your Health Care Team
- Cancer and Flu Shots
- Treatment Adherence: Taking Your Pills on Schedule – Why It Is So Important
- What are Biosimilars? Understanding Their Role in Cancer Treatment: Current and Future Perspectives
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Participating in Decisions about Your CarePart IV of Life with Cancer: A Guide to Getting the Best Care
- Cancer and The Workplace: Understanding Your Legal ProtectionsPart III of Life with Cancer: A Guide to Getting the Best Care
- Understanding the Costs of Care and Your Health Care CoveragePart II of Life with Cancer: A Guide to Getting the Best Care
- Trends in Oncology and Treatment Planning: What You Need to KnowPart I of Life with Cancer: A Guide to Getting the Best Care
- Taking Your Treatment on Schedule: Its Importance in Managing Cancer
- Care for Your Bones During & After Cancer Treatment: Tips to Improve Bone Health
- Participating in Decisions about Your CarePart V of Life with Cancer: A Guide to Getting the Best Care
- Medical Emergencies in Cancer Treatment
For Acute Lymphoblastic Leukemia
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Acute Myeloid Leukemia
- Update on CAR T-Cell Therapies
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Acute Myelogenous Leukemia (AML): Current Treatment Perspectives
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Acute Myeloid Leukemia (AML): Treatment Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Update on the Treatment of Acute Myelogenous Leukemia (AML)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Basal Cell Cancer
For Bladder Cancer
For Bone Cancer
For Brain Cancer
- Glioblastoma in Adults: Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- Glioblastoma in Adults: Treatment Updates
- Update on Glioblastoma in Adults
For Breast Cancer
- Early Stage Breast Cancer: New Treatment Approaches
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Lobular Breast Cancer: Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Updates in the Treatment of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 Positive Breast Cancer from the 45th Annual San Antonio Breast Cancer SymposiumPart II of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- Metastatic Breast Cancer in African Americans: New Treatments
- Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
- The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- Triple Negative Breast Cancer and African American Women
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
- Triple Negative Breast Cancer and African American Women
For Cervical Cancer
For Chronic Lymphocytic Leukemia
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
- Taking Your Blood Cancer Treatment on Schedule
- Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)
For Chronic Myelogenous Leukemia
- Update on CAR T-Cell Therapies
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Colorectal Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Advances in the Treatment of Colorectal Cancer
- Advances in the Treatment of Colorectal Cancer
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Colorectal Cancer Treatment: Progress and Advances
- Colorectal Cancer Treatment: Progress & Advances
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Advances in the Treatment of Colorectal Cancer
For Cutaneous T-Cell Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Diffuse Large B-Cell Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Diffuse Large B-Cell Lymphoma (DLBCL) Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Endometrial Cancer
For Follicular Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Follicular Lymphoma: Treatment Progress
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Progress in the Treatment of Follicular Lymphoma
- Taking Your Blood Cancer Treatment on Schedule
For Gastric Cancer
For Gastrointestinal Stromal Tumors
For Glioblastoma
- Glioblastoma in Adults: Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- Glioblastoma in Adults: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Update on Glioblastoma in Adults
For Head and Neck Cancer
For Hodgkin Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Kidney Cancer
For Leukemia
- Update on CAR T-Cell Therapies
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Acute Myelogenous Leukemia (AML): Current Treatment Perspectives
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Acute Myeloid Leukemia (AML): Treatment Updates
- Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Myelofibrosis
- Update on the Treatment of Acute Myelogenous Leukemia (AML)
- Update on CAR T-Cell Therapies
- Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
- Taking Your Blood Cancer Treatment on Schedule
- Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)
For Liver Cancer
For Lung Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diverse Populations Living with Non-Small Cell Lung Cancer
- Update on Small Cell Lung CancerPart I of Living with Small Cell Lung Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Non-Small Cell Lung Cancer: Biomarker Testing & Treatment TrendsPart II of Living with Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: What's NewPart I of Living with Non-Small Cell Lung Cancer
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Genomic Testing and Current Trends in the Treatment of Non-Small Cell Lung CancerPart III of Living with Non-Small Cell Lung Cancer
- Small Cell Lung Cancer: Treatment UpdatePart I of Living with Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: Treatment AdvancesPart I of Living with Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: What’s NewPart I of Living with Non-Small Cell Lung Cancer
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Diverse Populations Living with Non-Small Cell Lung Cancer
- Advances in the Treatment of Lung CancerPart I of Living with Lung Cancer
- Update on Small Cell Lung Cancer Treatments
- For Caregivers: Practical Tips for Coping with Your Loved One’s Lung CancerPart II of Living with Lung Cancer
- For Caregivers: Practical Tips for Coping with Your Loved One’s Lung Cancer During the HolidaysPart II of Life with Lung Cancer
For Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
- Follicular Lymphoma: Treatment Progress
- Diffuse Large B-Cell Lymphoma (DLBCL) Updates
- Marginal Zone Lymphoma (MZL): Treatment Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Update on Marginal Zone Lymphoma (MZL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Progress in the Treatment of Follicular Lymphoma
- Taking Your Blood Cancer Treatment on Schedule
For Mantle Cell Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Marginal Zone Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Marginal Zone Lymphoma (MZL): Treatment Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Update on Marginal Zone Lymphoma (MZL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Melanoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- People of Color Living with Skin Cancer
- Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
- New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell CancersPart I of Living with Advanced Skin Cancer and Melanoma
For Merkel Cell Carcinoma
For Mesothelioma
For Metastatic Breast Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Lobular Breast Cancer: Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Updates in the Treatment of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 Positive Breast Cancer from the 45th Annual San Antonio Breast Cancer SymposiumPart II of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- Metastatic Breast Cancer in African Americans: New Treatments
- Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
- The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
- Triple Negative Breast Cancer and African American Women
For Multiple Myeloma
- Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Multiple Myeloma
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Coping with the Stresses of Caregiving When Your Loved One Has Multiple MyelomaPart II of Living with Multiple Myeloma
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Multiple Myeloma
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Myelodysplastic Syndromes
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Myelofibrosis
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Myelofibrosis
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Myeloproliferative Neoplasms
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Myelofibrosis
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Non-Hodgkin Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Progress in the Treatment of Follicular Lymphoma
- Taking Your Blood Cancer Treatment on Schedule
For Ovarian Cancer
- Ovarian Cancer: Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- Ovarian Cancer: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Medical Update on Ovarian Cancer
For Pancreatic Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Peripheral T-Cell Lymphoma
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
- Update on CAR T-Cell Therapies
- Follicular Lymphoma: Treatment Progress
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Non-Hodgkin Lymphoma: Current Treatment Progress
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Taking Your Blood Cancer Treatment on Schedule
For Polycythemia Vera
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies